Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05532722 · ClinicalTrials.gov registry record · Phase 1
ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
A Phase 1 study of T-cell Large Granular Lymphocytic Leukemia, sponsored by Abcuro.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 8
- Study locations
NCT05532722 is a Phase 1 study of T-cell Large Granular Lymphocytic Leukemia that is active but no longer recruiting, run by Abcuro. The registered enrollment target is 21 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT05532722, a Phase 1 study of T-cell Large Granular Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Abcuro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 8
- Study locations
Study Summary
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Conditions Studied
Interventions
- DRUG ABC008
Study Locations (8)
California
- City of Hope - Duarte
- University of Southern California - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05532722
The ClinicalTrials.gov registry entry for NCT05532722 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abcuro, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-cell Large Granular Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which ABC008 is the first listed.
NCT05532722 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05532722 about?
NCT05532722 is a clinical study titled "ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)". An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
What is the current status of trial NCT05532722?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-09-28. Estimated completion is 2027-09.
What conditions does trial NCT05532722 study?
This clinical trial studies the following conditions: T-cell Large Granular Lymphocytic Leukemia.
What interventions are being tested in trial NCT05532722?
The interventions under investigation include: ABC008 (DRUG).
Who is sponsoring clinical trial NCT05532722?
This trial is sponsored by Abcuro, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05532722 being conducted?
This trial has 8 study locations across California, Massachusetts, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Large Granular Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.